IOV-4001 Clinical Trials (2026): 1 Studies for Metastatic Melanoma & Stage III Non-small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 IOV-4001 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Metastatic Melanoma & Stage III Non-small Cell Lung Cancer) and 53 total planned enrollment. 1 IOV-4001 clinical trial is actively recruiting at 10 U.S. sites across 7 states. Most recent activity: NCT05361174 (Sep 2029).
Where to Participate: All IOV-4001 Trial Sites in the U.S. (10 sites across 7 states)
Every actively recruiting IOV-4001trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | The Angeles Clinic and Research Institute | Los Angeles90025 | NCT05361174 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT05361174 | Map |
| FL | Orlando Health Cancer Institute | Orlando32610 | NCT05361174 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05361174 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205 | NCT05361174 | Map |
| KY | University of Louisville | Louisville40202 | NCT05361174 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05361174 | Map |
| NY | Weill Medical College of Cornell University | New York10022 | NCT05361174 | Map |
| OH | University of Cincinnati | Cincinnati45219 | NCT05361174 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT05361174 | Map |
IOV-4001 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting IOV-4001 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | P1/P2 | Unresectable Melanoma | 53 | Jul 2022 |
All IOV-4001 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05361174 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | P1/P2 | recruiting | 53 | Iovance Biotherapeutics, Inc. | Jul 2022 |
IOV-4001 clinical trials: frequently asked questions
- How many IOV-4001 clinical trials are there?
- 1 IOV-4001 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are IOV-4001 clinical trials recruiting in 2026?
- Yes — 1 IOV-4001 trial is actively recruiting in 2026, with 10 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is IOV-4001 being studied for?
- IOV-4001 is being studied for Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Unresectable Melanoma. The trials are grouped by indication on this page.
- Who sponsors IOV-4001 clinical trials?
- The lead sponsor across the most IOV-4001 trials is Iovance Biotherapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming IOV-4001as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: